MA-IMABIOTECH
ImaBiotech Group today announced the creation of an innovative global bioanalytical CRO with Pyxant Labs Inc. Colorado Springs and Salt Lake City sites. The integration of the expertise, innovation and analytical platforms of the companies to form a leading global bioanalytical services provider will provide a unique offering to pharmaceutical and cosmetic companies.
Encompassing unique proprietary drug and biomarker imaging (Mass Spectrometry Imaging), multi-omics, spatialomics capabilities and well-established high performance bioanalytical GLP services, the combined platforms will offer access to a unique set of services spanning the drug development cycle, from early-stage discovery through Phase IV. These services reduce the rate of failure and accelerate the development of safer therapies. In conjunction to the operation, the company received a majority investment from ArchiMed SAS (“Archimed”), a leading private equity fund focused on the healthcare sector.
This deal enables a continuing commitment to further extend these specialized capabilities, creating a major player focused exclusively on bioanalytical excellence where the deep-science paradigm, a relentless focus on customer service, and innovative proprietary technology will enable and accelerate therapeutic innovation for our clients.
“I am very pleased to expand our activities in North America and Europe with Pyxant Labs and Archimed,” said former founder and CEO of ImaBiotech, Jonathan Stauber, PhD. “Archimed brings exceptional healthcare expertise with insight into advanced bioanalytical services, and the combination of Pyxant Labs’ established bioanalytical capabilities with ImaBiotech’s innovative imaging technologies will provide a unique service offering to our customers in the US, Europe and Asia, representing a tremendous opportunity to grow in the CRO market.”
“ImaBiotech’s deep-science paradigm and focus on customer service were two essential characteristics in common with our business paradigms, which motivated us toward this combination,” commented Maurice Gaubatz, CEO of Pyxant Labs. "Joining forces with Jonathan’s organization bridges ImaBiotech’s unique mass spectrometry imaging capabilities with Pyxant Labs’ regulatory development bioanalytical services and provides coverage from early research through Phase IV development. The combined enterprise creates an international footprint and leading standing among CROs exclusively focused on mass spectrometry bioanalytical excellence.”
The transaction is subject to customary closing conditions and is expected to close in the second quarter of 2021.
About ImaBiotech www.imabiotech.com
ImaBiotech is a bioanalytical CRO with facilities in Boston (MA, USA) and Lille (Eurasante Park, France). ImaBiotech combines innovative mass spectrometry imaging and spatial biology (histology, multi-omics, spatialomics) techniques in order to decipher the complexity of drug activities. The combination of unique capabilities with advanced digital pathology tools makes possible the measurement of drug activity and drug response, simultaneously, at the single cell level. This performance enables comprehensive drug efficacy evaluation from preclinical to clinical stages.
About Pyxant Labs www.pyxant.com
Founded in 2000, Pyxant Labs provides innovative bioanalytical solutions for advancing leading-edge and challenging drug development programs from translation through NDA approval. Utilizing high resolution mass spectrometry and traditional LC-MS/MS platforms, the Colorado Springs site is recognized for its fast-turnaround drug discovery services, unique expertise quantitating delivery mechanisms for RNA therapeutics, anticipatory customer service, and superior regulatory compliance.
About ArchiMed www.archimed-group.eu
ArchiMed is a leading private equity firm focused exclusively on the healthcare industry. ArchiMed’s strategy is based upon healthcare specialization, integrated private equity, medical and operating expertise, and its unique trans-Atlantic platform that supports growth through internationalization. Over the last 20 years, ArchiMed’s leadership team has directly managed and invested in over 40 small to large-size healthcare companies globally, representing over €5 billion of invested capital. ArchiMed currently manages nearly €2 billion in assets across four funds, small-cap focused MED I and MED II, gene & cell therapy focused PolyMED and mid-cap-focused MED Platform I. The latter is Europe’s largest healthcare fund at €1 billion. ArchiMed is an impact investor and a signatory of the Principles for Responsible Investment , pledged to uphold the United Nations’ Sustainable Development Goals .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005490/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Announces Appointment of Brett Icahn and Richard Mulligan to Board of Directors22.10.2025 22:15:00 CEST | Press release
IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today announced the appointment of Brett Icahn and Richard Mulligan, Ph.D., to its board of directors, effective Oct. 20. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022380951/en/ Brett Icahn (Photo: IFF) These appointments follow the company’s previously disclosed cooperation agreement with Icahn Capital LP and its affiliates. Icahn serves as the Icahn designee to the IFF board, replacing Vincent Intrieri, and Mulligan joined as the mutually agreed independent director, replacing Margarita Paláu-Hernández. Intrieri and Paláu-Hernández stepped down from the board on Oct. 20. Icahn has been named to the Board’s Audit Committee and Transaction Committee, and Mulligan has been named to the Board’s Innovation Committee. “We are very pleased to welcome Brett and Richard to the IFF board,” said Kevin O’Byrne, chair of the IFF boa
OpenAI, Oracle and Vantage Data Centers Announce Stargate Data Center Site in Wisconsin22.10.2025 22:05:00 CEST | Press release
Vantage’s $15B+ investment in Port Washington represents the future of sustainable digital infrastructure with zero-emission energy resources, water-positive operations and billions in regional economic growth OpenAI, Oracle and Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced plans to develop a data center campus outside Milwaukee in Port Washington, Wisconsin. The new campus is part of OpenAI and Oracle’s previously announced partnership to invest up to 4.5 gigawatts of additional Stargate capacity and is the Midwest site that was recently announced as part of OpenAI’s Stargate expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022873578/en/ Vantage Data Centers’ $15B+ campus in Port Washington, Wisconsin represents the future of sustainable digital infrastructure. The campus will feature four cutting-edge data centers providing close to a gigawatt of AI capacity
Pure Lithium Opens New Chicago Headquarters, Advancing Commercialization of Its Lithium Metal Battery22.10.2025 19:24:00 CEST | Press release
Pure Lithium Corp., a disruptive vertically integrated lithium metal battery technology company, officially opened its new headquarters in Chicago’s Fulton Market district with a ribbon cutting ceremony Tuesday attended by community and business leaders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022239586/en/ From left: Ken Hoffman, Pure Lithium Special Advisor; Dr. Yuan Gao, Member of Pure Lithium Scientific Advisory Board; Derek Willis, Vice President of Commercial Development at Oxy Low Carbon Ventures and Pure Lithium Board Director; Miss Illinois Nitsaniyah Fitch; Chicago Mayor Brandon Johnson; Pure Lithium Founder, Chairman & CEO Emilie Bodoin; Illinois State Senator Lakesia Collins; Former Massachusetts Governor & Pure Lithium Board Director William F. Weld; Lisa Clemmons-Stott, Senior Economic Advisor, Director’s Office, Illinois Department of Commerce and Economic Opportunity The opening marks a milestone in
Doha Debates Launches New Debate Season with Al Jazeera22.10.2025 19:07:00 CEST | Press release
The new season brings global voices together for truth-seeking discussions Qatar Foundation’s Doha Debates launched a new season of its flagship program, Doha Debates, on October 21, co-produced with Al Jazeera Digital. The upcoming season features high-profile guests, bold global themes and a renewed focus on open, truth-seeking dialogue. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022828303/en/ Qatar Foundation’s Doha Debates launches new debate season, bringing global voices together for truth-seeking discussions. (photo: AETOSWire) Airing weekly on Tuesdays through December 9, the eight-episode season explores three overarching themes—freedom, grand narratives and family. Each episode features leading thinkers and young changemakers engaging in timely conversations on the issues shaping humanity, ranging from meritocracy to social media; from love to architecture; from ancient traditions to the future of work. The
Picsart, Gen Z’s Preferred Digital Content Creation Platform, Takes LinkedIn Creators to Dracula’s Castle for “Why Your Marketing Sucks” Halloween Campaign22.10.2025 18:23:00 CEST | Press release
Picsart, the world’s leading digital creation platform, has announced the release of its new Halloween campaign and ebook, Why Your Marketing Sucks: a highly visual, tongue-in-cheek guide to the scariest mistakes marketers make and how to avoid them. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022722043/en/ Why Your Marketing Sucks Ebook by Picsart The campaign, running from October 15 through October 31, combines horror-themed storytelling with practical marketing advice and expertise. Its centerpiece, the Why Your Marketing Sucks ebook, was co-created by Picsart and five top LinkedIn marketing influencers during an exclusive brand trip to Transylvania to visit Bran Castle — thought to be the home of Count Dracula himself. Picsart’s COO and Co-Founder, Mikayel Vardanyan, said “Gen Z represents more than 25% of today’s workforce. Picsart has been supporting this demographic for 15 years — more than half of our users ar
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom